logo
Many new moms in Texas don't know they qualify for a year of Medicaid, doctors say

Many new moms in Texas don't know they qualify for a year of Medicaid, doctors say

Yahoo30-01-2025

Almost all of the pregnant women Dr. Joshua Splinter sees at his rural East Texas practice are on Medicaid. For years, he would treat these patients during pregnancy, deliver their babies and then start the mad dash to squeeze in a follow-up visit before they lost insurance just eight weeks after giving birth.
This just didn't work for him or his patients. He'd get someone on a treatment plan for a chronic condition, but then the hormone and weight changes after childbirth would require different interventions. He'd see early signs of postpartum depression or partner violence, and then lose contact with the patient once she lost insurance.
'These aren't things where I start a medication and we're done,' he said. 'This requires close follow-up with continued treatment and non-medical intervention, and we can't get that done in two months.'
So when the Texas Legislature voted to extend postpartum Medicaid to a full year in 2023, Splinter was ecstatic. This was going to be a 'game changer' for his patients, he said.
But almost two years later, many of his patients and those like them across the state are still struggling to get the full range of health care they were promised. It took almost a year for the extended coverage to go into effect, leaving many of his patients in limbo, and even now, they're still often falling through the cracks in Texas' health care system.
The number of pregnant and postpartum Texans enrolled in Medicaid has almost doubled since before the pandemic, to more than 265,000. But many patients are unaware that they are still covered for an additional 10 months, according to a survey from Texans Care for Children, a health advocacy group. New moms report being unable to access the physical and mental health services covered by Medicaid, and doctors say changes are needed to ensure the workforce, reimbursement rates and coverage can keep up with a full year of need.
As the Legislature returns, Diana Forester, health policy director with Texans Care for Children, said there's still much work to be done, such as increasing provider awareness and patient access, to ensure new moms are fully benefiting from this extended coverage.
'You can't just turn on this extended coverage and expect that to be the end,' Forester said. 'We as a state need to figure out what postpartum care looks like in Texas … Our leaders have an opportunity to make that work better for families, but it's not there yet.'
When Gov. Greg Abbott signed House Bill 12 into law in May 2023, Texas became the 41st state to extend postpartum Medicaid to 12 months. It was a victory years in the making, after several sessions of advocacy from health care providers, maternal health experts and moms themselves.
The state almost passed it in 2021, after the federal COVID relief package eased the way for states to get this extended coverage approved, but the Legislature instead passed a six-month extension that the federal government deemed 'not approvable.'
But when the Legislature returned in 2023, Roe v. Wade had been overturned, abortion was virtually banned in Texas, and there was new momentum around bills to support pregnant women and families.
Sen. Lois Kolkhorst, a Republican from Brenham, carried the bill on the Senate side, and said at a hearing that extending coverage was about making sure 'women who give birth to children in this pro-life environment are cared for … You cannot raise a child without being healthy.'
The bill passed with overwhelming bipartisan support, and Abbott signed it into law in May 2023. HHSC submitted the waiver request to the federal government, which approved it last January. The state began offering extended coverage March 1, 2024.
After all that back and forth, half-steps and setbacks, many doctors were unaware that the extended coverage was actually in effect, Texans Care for Children found in its survey. Some doctors found out for the first time through their billing departments. Several said they wanted more outreach from the state health agency and the managed care organizations, like a flyer or training for doctors.
'The state could do a lot more in that area,' said Helen Kent Davis, a senior policy advisor to the Texas Academy of Family Physicians. 'They've tried, to the extent that there's funding for outreach, to get the word out, but there's more to be done, for sure.'
In a statement, a spokesperson for Texas' Health and Human Services Commission said they used a variety of approaches to inform the public about these changes, including calls and webinars, provider notices, posting information to their websites and working with managed care organizations to get the word out.
But knowledge gaps remain, Kent Davis said. As an example, she said pediatricians have not been educated on this change the way OB/GYNs and family physicians have. Since they're seeing the baby regularly, these doctors could be a key ally in making sure the mom knows she still has coverage.
Doctors also report confusion about who is responsible for overseeing this year of health care. Texas Medicaid changed its policy to allow an OB/GYN to serve as a patient's doctor for the whole year, but the survey found many doctors across specialties were not aware of that and, when asked, said they would prefer patients be handed off to a primary care provider.
'Patients have been seeing their obstetrician this whole time and the health care system is not good at handing them back to a primary care physician for the rest of that period,' Kent Davis said. 'This is a significant culture shift for patients and providers.'
And with a shortage of primary care physicians, especially in rural areas, more coverage doesn't automatically translate into more health care. One new mother in Mineral Wells told Texans Care for Children she would have to travel almost an hour to Fort Worth to see a primary care provider.
'Every day, I get really bad headaches… very bad headaches,' she said. 'And it's getting more consistent. I just deal with it.'
In a state where almost half of all pregnant women typically lost insurance two months after giving birth, convincing new moms that they can continue engaging with the health care system has been an uphill battle. Home-visiting nurses, community health workers and others who work closely with new moms report significant confusion and resistance from patients.
'They really had to talk their patients into accessing care, essentially, because they're so used to not having coverage and so worried about the cost and having to absorb that personally,' Forester said.
It didn't help matters that this extended coverage finally went into effect amid a historic fracture to the state's Medicaid system. For three years during the pandemic, states kept everyone enrolled in Medicaid, but in spring 2023, were allowed to move people off their rolls.
Texas removed more people, including postpartum women, faster than any other state, against federal guidelines, The Texas Tribune and ProPublica found. The state required almost everyone to resubmit documents proving their eligibility, rather than relying on automatic approvals like other states. More than a million people lost coverage for bureaucratic reasons like failing to return a form. The state has acknowledged some errors, which they later fixed.
Amid this upheaval, Texas implemented the extended coverage, including reinstating women who lost Medicaid at two months but were still in their one-year postpartum period.
'It was really confusing for members who were like, 'you terminated my Medicaid a month ago, I have the notice,' and then they're told that it's being turned back on for a few more months,' Forester said. 'And it's really hard for a doctor to be able to educate their patients when it's totally dependent on where they are in the postpartum period.'
Splinter said he's had at least a dozen patients over the last year who had to call their managed care organization to get their coverage reinstated.
'I'm having to act a little like a social worker and educate the patient on who they need to call and what they need to say,' he said. As a family physician trained in high-risk pregnancies practicing in an underserved area, Splinter said, 'there's only so much of me to go around, especially if I have to spend more time on non-doctor work like this.'
A spokesperson for the state's health agency said everyone who was enrolled in Medicaid or CHIP during their pregnancy were automatically reinstated for the remainder of their postpartum period. While some of this is naturally sorting itself out the longer the policy is in effect, Splinter said he was surprised at the work his patients had to do to get the coverage they qualified for.
'You're leaving pregnant patients and new moms to fight up the chain and solve it themselves from the bottom' he said. 'That just isn't the right way to be doing this.'
As more new moms are able to take advantage of this extended coverage, doctors and advocates hope the health care system is able to meet their needs. In the short term, Splinter said, he's hopeful that the state can proactively go back through its records and ensure women who qualify for this coverage are actually getting it.
In the long term, the state needs to address long-standing structural problems facing its health care system, like significant shortages in primary care and mental health providers. Advocates are pushing for increased reimbursement rates and reforms to the bureaucracy that providers must go through to accept Medicaid, to ensure doctors are willing to see these patients.
They also want Medicaid coverage to catch up to the extended time period women can receive these benefits.
For example, Texas Medicaid covers one postpartum depression screening, even though national groups recommend at least four, Kent Davis said. With an extra ten months of coverage, that's a lot more touch points for doctors to be screening patients for mental health needs. She'd also like to see Medicaid cover lactation support among other needs that can emerge in the first 12 months postpartum.
'It takes a comprehensive strategy,' Kent Davis said. 'Obviously the coverage issue was one part to address and, and we're so happy that we were able to pass House Bill 12. But now that we have this coverage, what do we do to make sure women can get it?'
Disclosure: Texans Care for Children has been a financial supporter of The Texas Tribune, a nonprofit, nonpartisan news organization that is funded in part by donations from members, foundations and corporate sponsors. Financial supporters play no role in the Tribune's journalism. Find a complete list of them here.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Multi-Blood Monitoring System Market is expected to reach USD 3.9 billion by 2034, with a 6.4% CAGR growth
Multi-Blood Monitoring System Market is expected to reach USD 3.9 billion by 2034, with a 6.4% CAGR growth

Yahoo

time38 minutes ago

  • Yahoo

Multi-Blood Monitoring System Market is expected to reach USD 3.9 billion by 2034, with a 6.4% CAGR growth

Multi Blood Monitoring System Market Overview 2025-2034 Luton, Bedfordshire, United Kingdom, June 10, 2025 (GLOBE NEWSWIRE) -- The global multi blood monitoring system market is witnessing dynamic expansion, with its value estimated at approximately USD 2.1 billion in 2024, and expected to grow to around USD 3.9 billion by 2034. This translates into a Compound Annual Growth Rate (CAGR) of 6.4% over the forecast period from 2025 to 2034. This growth is primarily fueled by the increasing demand for accurate, efficient, and accessible blood monitoring technologies across various healthcare applications. Download PDF Brochure: These devices are critical in the management of chronic diseases such as diabetes and cardiovascular conditions. As the global burden of such illnesses escalates, particularly among aging populations and across developing regions, the need for real-time, portable, and user-friendly blood monitoring systems has become more urgent than ever. Market Drivers and Opportunities Several underlying factors are contributing to the expansion of this market. Among the most significant drivers is the rising prevalence of chronic diseases. The World Health Organization (WHO) forecasts that by 2030, chronic diseases will account for over 75% of global deaths, highlighting the growing necessity for continuous and reliable health monitoring tools. Moreover, technological advancements in wearable devices, mobile health apps, and telemedicine have revolutionized the way blood monitoring is conducted. These innovations have led to more personalized and preventive healthcare solutions, allowing patients to self-monitor in real-time, often without the need for clinical supervision. This trend is particularly appealing to tech-savvy consumers and younger demographics who are increasingly proactive about their health. Emerging economies also present significant growth potential. With rising healthcare expenditure, expanding middle-class populations, and improving medical infrastructure, regions such as Asia-Pacific, Latin America, and parts of the Middle East are becoming fertile grounds for market expansion. Additionally, the integration of AI and machine learning into monitoring systems is creating opportunities for predictive diagnostics and tailored treatment strategies, revolutionizing the future of personalized medicine. Key Market Challenges Despite its positive growth outlook, the multi blood monitoring system market faces certain challenges. One of the primary obstacles is the complex regulatory landscape. Medical device manufacturers must navigate stringent approval processes, especially in developed regions like North America and Europe. These regulations, although necessary for ensuring safety and efficacy, often delay product rollouts and increase development costs. Supply chain disruptions have also impacted the market, particularly during and after the COVID-19 pandemic. Delays in procuring raw materials, component shortages, and transportation hurdles have affected production timelines and product availability. Furthermore, high costs associated with technologically advanced blood monitoring devices can be a deterrent for adoption, especially in price-sensitive markets. Healthcare providers are often pressured to deliver cost-effective solutions, which can limit investments in premium monitoring systems. Another pressing concern is data security and patient privacy. With the growing digitalization of healthcare and increased reliance on cloud-based data storage, ensuring the protection of sensitive patient information has become paramount. Regulatory frameworks such as HIPAA and GDPR are placing additional burdens on companies to fortify their cybersecurity measures. Market Segmentation Analysis By Product Type The market is segmented into several product categories including continuous glucose monitoring (CGM) systems, blood pressure monitors, cholesterol testing devices, and complete blood count (CBC) test devices. Among these, CGM systems are emerging as the dominant product category, accounting for roughly 35% of market share. The increased prevalence of diabetes globally has significantly contributed to this trend. Blood pressure monitoring devices come in second, capturing an estimated 25% of the market, owing to the widespread incidence of hypertension. Cholesterol testing devices follow with a 15% market share, as more individuals become aware of the risks associated with high cholesterol levels. By End User Hospitals are the largest consumers of multi blood monitoring systems, accounting for nearly 45% of the market share. The growing number of patients and a strong focus on preventive healthcare are driving demand in this segment. Diagnostic laboratories represent the second-largest user group, contributing 30% of market revenue, largely due to the complexity and volume of testing they handle. Homecare settings have gained traction, especially post-pandemic, and currently hold around 20% of the market. The convenience of remote monitoring has been widely appreciated, particularly among the elderly and chronically ill patients who prefer in-home testing. By Technology From a technology standpoint, wearable technologies are transforming the landscape, projected to represent 40% of the market by 2034. These devices offer unmatched convenience and user engagement. Invasive technologies still maintain a solid 45% market share, particularly in clinical environments where precision is critical. Meanwhile, non-invasive technologies are growing steadily and are expected to hold 15% of the market, driven by advancements in optical and sensor-based innovations. By Application Diabetes management remains the top application area, constituting about 50% of the total market. As diabetes rates continue to climb worldwide, the demand for continuous and accurate glucose monitoring devices is increasing proportionally. Cardiovascular monitoring is another important application, making up 30% of the market, while fitness and wellness monitoring is growing rapidly, accounting for around 15% as consumers adopt proactive health strategies. By Distribution Channel In terms of distribution, offline sales still dominate with a 55% market share, primarily due to the preference for in-person consultations and product demonstrations in hospital and clinical settings. Online channels, however, are growing fast and now represent 30% of sales, fueled by digital adoption and e-commerce growth. Direct sales—through specialized distributors—comprise the remaining 15%, ensuring product customization and support services. Browse full Report - Market Segmentation Product Type - Continuous Glucose Monitoring Systems - Blood Pressure Monitoring Devices - Cholesterol Testing Devices - Complete Blood Count Test Devices - Others End-User - Hospitals - Diagnostic Laboratories - Homecare Settings - Research Institutions Technology - Wearable Technology - Non-invasive Technology - Invasive Technology Application - Diabetes Management - Cardiovascular Monitoring - Blood Disorders Management - Fitness and Wellness Monitoring Distribution Channel - Online Sales - Offline Sales - Direct Sales Region - North America - Europe - Asia Pacific - Latin America - Middle East & Africa Regional Outlook Regionally, North America leads the global market, accounting for approximately 40% of total revenues in 2024. This dominance is attributed to advanced healthcare infrastructure, favorable regulatory support, and the presence of leading industry players. Europe follows with a 30% market share, supported by robust public healthcare systems and a rising focus on personalized medicine. The Asia-Pacific region is the fastest-growing market, projected to expand at a CAGR of 7.5%. This growth is driven by large patient populations, increasing disposable income, and government initiatives to enhance healthcare access. Countries such as China, India, and Japan are key contributors to this growth trajectory. Latin America and the Middle East & Africa collectively account for a modest share (5% in 2024) but are poised for steady growth due to improvements in healthcare infrastructure and expanding awareness about chronic disease management. Key Competitors Abbott Laboratories Roche Holding AG Siemens Healthineers Becton, Dickinson and Company (BD) Medtronic plc Nova Biomedical Johnson & Johnson Dexcom, Inc. Arkray, Inc. Ascensia Diabetes Care Terumo Corporation GlySens Incorporated Insulet Corporation Elysium Health LabCorp Recent Industry Developments Several companies have made notable strides in advancing this market: Abbott Laboratories launched FreeStyle Libre 3, a real-time glucose monitor with a discreet sensor, in June 2023, strengthening its lead in the CGM space. In April 2023, Roche formed a strategic partnership with a wearable tech firm to integrate blood monitoring devices with smart devices, enhancing patient engagement and adherence. Siemens Healthineers acquired an AI-based diagnostics company in August 2023, signaling a deeper focus on precision diagnostics through data analytics. Dexcom received FDA approval in September 2023 for a no-fingerstick CGM device, which is likely to broaden its user base and redefine market standards. Medtronic expanded its product line into Asia and Africa in July 2023, targeting underserved markets and accelerating growth in emerging economies. This report is also available in the following languages : Japanese (マルチ血液モニタリングシステム市場), Korean (다혈액 모니터링 시스템 시장), Chinese (多血液监测系统市场), French (Marché des systèmes de surveillance sanguine multi-sang), German (Markt für Multi-Blutüberwachungssysteme), and Italian (Mercato dei sistemi di monitoraggio multi-sangue), etc. Request Sample Pages: More Research Finding – Medical Refrigerated Market The global medical refrigerated market is valued at approximately $6.5 billion in 2024, with projections indicating a potential increase to around $10 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of approximately 4.5% during the forecast period from 2025 to 2034. Cardiovascular Monitoring Devices Market The cardiovascular monitoring devices market is valued at approximately $10.5 billion in 2024, with projections indicating substantial growth, reaching around $16.8 billion by 2034. This translates to a robust Compound Annual Growth Rate (CAGR) of approximately 4.8% during the forecast period from 2025 to 2034. Non Invasive Hemodynamic Detection System Market The global Non-Invasive Hemodynamic Detection System market is valued at approximately USD 2.1 billion in 2024, with strong growth anticipated over the next decade. By 2034, the market is projected to reach around USD 4.5 billion, representing a Compound Annual Growth Rate (CAGR) of approximately 8.0%. Disposable Syringes and Accessories Market The global disposable syringes and accessories market is valued at approximately $7.5 billion in 2024, with a projected growth trajectory that anticipates reaching around $13 billion by 2034. This translates to a compound annual growth rate (CAGR) of about 6.1% over the 2025-2034 period. Blood Collection Mixer Market The blood collection mixer market is valued at approximately $250 million in 2024 and is projected to reach around $400 million by 2034. This growth represents a Compound Annual Growth Rate (CAGR) of about 5.1% during the forecast period from 2025 to 2034. Hemochromatosis Treatment Market The global hemochromatosis treatment market is valued at approximately $2.1 billion in 2024. The market is anticipated to grow significantly, reaching an estimated $3.5 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period of 2025–2034. Gestational Trophoblastic Disease Market The gestational trophoblastic disease (GTD) market is currently valued at approximately $1.8 billion in 2024, with projections indicating a potential growth to around $3.1 billion by 2034. This represents a compound annual growth rate (CAGR) of approximately 6.2% during the forecast period from 2025 to 2034. Septicemia Diagnostic Market The global septicemia diagnostics market is valued at approximately $1.5 billion in 2024, with projections indicating a growth to around $2.9 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 7.5% for the period from 2025 to 2034. Single Use Safety Lancet Market The global market for single-use safety lancets, valued at approximately $1.2 billion in 2024, is expected to reach around $2.5 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period from 2025 to 2034. Microalbuminuria Test Strip Market The microalbuminuria test strip market is poised for notable growth, valued at approximately $1.2 billion in 2024. This market is projected to expand to around $2.4 billion by 2034, indicating a robust growth trajectory. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at 7.3%. Monkeypox Virus Detection Reagent Market The monkeypox virus detection reagent market is anticipated to reach approximately $150 million in value by 2024, driven by heightened awareness and diagnostic needs amid ongoing public health surveillance. The market is projected to expand significantly, reaching an estimated $300 million by 2034, reflecting sustained interest in infectious disease diagnostics and preparedness. Blood Tester Market The global blood testing market is anticipated to reach a value of approximately $75 billion in 2024, driven by increasing prevalence of chronic diseases, rising health awareness, and advancements in diagnostic technologies. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% from 2025 to 2034, potentially reaching over $135 billion by 2034. HBsAg ELISA Test Kit Market The HBsAg ELISA Test Kit market is poised for robust growth, with a current market value estimated at approximately $1.5 billion in 2024. Driven by the increasing global prevalence of Hepatitis B, ongoing advancements in diagnostic technologies, and rising healthcare expenditures, the market is projected to reach around $2.8 billion by 2034. This trajectory indicates a Compound Annual Growth Rate (CAGR) of approximately 6.5% from 2025 to 2034. Blood Plasma Extractor Market The global blood plasma extractor market is valued at approximately $1.2 billion, driven by rising demand for plasma-derived therapies in treating various diseases. The market is projected to reach about $2.9 billion by 2034, reflecting an impressive Compound Annual Growth Rate (CAGR) of approximately 9.2% from 2025 to 2034. Amphetamine Test Kit Market The amphetamine test kit market is projected to reach a value of approximately $500 million in 2024, with expectations to grow to around $900 million by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 6% during the forecast period of 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio

GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients
GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients

Yahoo

time39 minutes ago

  • Yahoo

GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients

ATLANTA, GA - June 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and solid tumors, today announced that clinical data for its next-generation COVID-19 multi-antigen vaccine candidate, GEO-CM04S1, will be presented at the European Hematology Association (EHA) 2025 Hybrid Congress, taking place June 1215, 2025, in Milan, Italy and online. Alexey V. Danilov, M.D., Ph.D., Associate Director of the Toni Stephenson Lymphoma Center and Professor in the Department of Hematology and Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center in Duarte, California, will present a poster titled: "MVA-Based GEO-CM04S1 Vaccine Results in Improved Cellular Immune Response in Patients with Chronic Lymphocytic Leukemia (CLL) Compared with mRNA-Based Vaccine: Initial Results of a Phase II Randomized Study". The poster will be featured on Saturday, June 14, 2025, from 18:30 to 18:30 CEST in the Poster Hall, as part of the session on Infections in Hematology (including supportive care/therapy). The presentation will highlight initial results from a Phase II randomized clinical trial highlighting the superior cellular immune response of GEO-CM04S1 compared to an authorized mRNA-based COVID-19 vaccine in CLL patients - a population known to exhibit suboptimal protective responses to COVID-19 and other vaccines due to immune dysfunction. The findings will underscore the differentiated mechanism and clinical potential of the GeoVax MVA multi-antigen platform, particularly in immunocompromised individuals. "GEO-CM04S1 continues to show promise as a vaccine option for populations with suboptimal protection from existing COVID-19 vaccines," said Kelly T. McKee, Jr., M.D., Chief Medical Officer of GeoVax. "We are proud to have these important data showcased at EHA2025, reflecting the real-world needs of patients with hematologic malignancies." About GEO-CM04S1 GEO-CM04S1 is a multi-antigen COVID-19 vaccine designed using a synthetic Modified Vaccinia Ankara (MVA) vector platform. The vaccine expresses both spike (S) and nucleocapsid (N) antigens of SARS-CoV-2, aiming to provide broader and more durable immune protection. It is currently being evaluated in Phase 2 clinical trials in both immunocompromised and healthy adults. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Company Contact:info@ Investor Relations Contact:geovax@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store